Javier Puente Vázquez (Javier Puente)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Childhood Cancer

Pain Management

Papillary Thyroid

Top Venues

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Javier Puente Vázquez, Ferrán Algaba Arrea, Óscar Buisán Rueda, Daniel Castellano Gauna, Ignacio Durán, Juan José Fernández Ávila, Alfonso Gomez-Iturriaga, Mariano José Parada Blázquez, Daniel Pérez Fentes, Gemma Sancho Pardo, Juan Antonio Vallejo Casas, Paula Gratal, María Teresa Pardo, Vicente Guillem Porta
Criteria and indicators to evaluate quality of care in genitourinary tumour boards. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 26 (7) (2024)
Javier Puente Vázquez, Ferrán Algaba Arrea, Óscar Buisán Rueda, Daniel Castellano Gauna, Ignacio Durán, Juan José Fernández Ávila, Alfonso Gomez-Iturriaga, Mariano José Parada Blázquez, Daniel Pérez Fentes, Gemma Sancho Pardo, Juan Antonio Vallejo Casas, Paula Gratal, María Teresa Pardo, Vicente Guillem Porta
Criteria and indicators to evaluate quality of care in genitourinary tumour boards. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 26 (7) (2024)
Javier Puente Vázquez, Ferrán Algaba Arrea, Óscar Buisán Rueda, Daniel Castellano Gauna, Ignacio Durán, Juan José Fernández Ávila, Alfonso Gomez-Iturriaga, Mariano José Parada Blázquez, Daniel Pérez Fentes, Gemma Sancho Pardo, Juan Antonio Vallejo Casas, Paula Gratal, María Teresa Pardo, Vicente Guillem Porta
Criteria and indicators to evaluate quality of care in genitourinary tumour boards. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
Javier Puente Vázquez, Ferrán Algaba Arrea, Óscar Buisán Rueda, Daniel Castellano Gauna, Ignacio Durán, Juan José Fernández Ávila, Alfonso Gomez-Iturriaga, Mariano José Parada Blázquez, Daniel Pérez Fentes, Gemma Sancho Pardo, Juan Antonio Vallejo Casas, Paula Gratal, María Teresa Pardo, Vicente Guillem Porta
Criteria and indicators to evaluate quality of care in genitourinary tumour boards. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 26 (7) (2024)
Joan Carles, Rafael Antonio Medina-López, Javier Puente Vázquez, Álvaro Gómez-Ferrer, Francisco Javier Casas-Nebra, María Isabel Sáez Medina, Maria J Ribal, Alfredo Rodríguez Antolín, José Luís Álvarez-Ossorio, José Francisco Suárez Novo, Cristina Moretones Agut, Shankar Srinivasan, Jorge Ortiz, Karim Fizazi
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. Future oncology (London, England) (2023)
Alejandra Bernardini, Marta Dueñas, María Cruz Martín-Soberon, Carolina Rubio, Cristian Suarez-Cabrera, Raquel Ruiz-Palomares, Ester Munera-Maravilla, Sara Lázaro, Iris Lodewijk, Daniel Rueda, David Gómez-Sánchez, Teresa Alonso Gordoa, Javier Puente Vázquez, Álvaro Pinto, Pilar González-Peramato, Carlos Aguado, Mercedes Herrera, Flora López, Victor M G Martinez, Lucía Morales, Daniel Castellano, Jesus M Paramio, Guillermo de Velasco
Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer. Cancers 14 (2) (2022)
Daniel Herrero Rivera, Carmen Garrigós Vacas, Laura Marcos Kovandzic, Javier Puente Vázquez, Lucía A Alonso, Begoña Mellado González, Verónica Calderero Aragón, Enrique Grande, Raquel Luque Caro, Juan A Virizuela Echaburu, Juan Francisco Rodriguez-Moreno, Ainara A Etxebarria, Cristina Rodríguez-Antona, Ignacio Duran
Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics 23 (11) (2022)
Javier Puente Vázquez, Aranzazu González-Del-Alba, Núria Sala-Gonzalez, María José Méndez-Vidal, Alvaro Pinto, Ángel Rodríguez, José Miguel Cuevas Sanz, Jacobo Rodrigo Muñoz Del Toro, Eduardo Useros Rodríguez, Ángela García García-Porrero, Sergio Vázquez
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC cancer 19 (1) (2019)